Table 1.
Demographics of participants.
| Variables | ChAdOx1 (AstraZeneca/Oxford) Group (n = 65) | BNT162b2 (Pfizer) Group (n = 50) |
p Value |
|---|---|---|---|
| Age, years | |||
| Mean ± SD (range) | 41.7 ± 13.6 (23–72) | 43.5 ± 9.35 (24–60) | 0.411 |
| Sex | 0.826 | ||
| Male | 16 (24.6) | 11 (22.0) | |
| Female | 49 (75.4) | 39 (78.0) | |
| Previous allergy/anaphylaxis history | 0.079 | ||
| None | 62 (95.4%) | 41 (82.0%) | |
| Drug/Food | 2 (3.1%) | 5 (10.0%) | |
| Anaphylaxis to drug/food | 0 | 2 (4.0%) | |
| Vaccine allergy | 0 | 2 (4.0%) | |
| Vaccine anaphylaxis | 1 (1.5%) | 0 | |
| Days post 2nd vaccination, mean/median (range) | 56.1/56.0 (41–57) | 56.9/56.0 (54–63) | 0.999 |